CLINICAL_TRIALS
trial_result
· 2013-05-15
Clinical Trial Update: Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis [Phase 3]
Summary
A Phase 3 clinical trial update reports on the safety profile of etanercept 50 mg administered twice weekly in adults with psoriasis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Psoriasis | Phase 3 | Status: COMPLETED